The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Enhancing lung cancer surgical quality: Insights from a national quality improvement collaborative.
 
Kelley Chan
No Relationships to Disclose
 
Eileen Reilly
No Relationships to Disclose
 
Ryan Jacobs
No Relationships to Disclose
 
Tashea Coates
No Relationships to Disclose
 
Amanda Francescatti
No Relationships to Disclose
 
Kimberly Rodriguez
No Relationships to Disclose
 
Raheem Bell
Research Funding - AstraZeneca
 
Linda Martin
Honoraria - AstraZeneca; Genentech
Consulting or Advisory Role - AstraZeneca; Genentech; On Target Laboratories
Speakers' Bureau - Bristol-Meyers Squibb; Johnson and Johnson
 
Matthew Facktor
No Relationships to Disclose
 
Kirtee Raparia
No Relationships to Disclose
 
John Hamm
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Jazz Pharmaceuticals; Meda Pharmaceuticals; Novocure
Research Funding - Abbvie (Inst); Amgen (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Beijing Avistone Biotechnology Co., Ltd. (Inst); BioNTech SE (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); BrightPath Biotheraputics (Inst); Bristol-Myers Squibb (Inst); Cancer Research and Biostatistics (Inst); Celgene (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Dana-Farber Cancer Institute (Inst); Deciphera (Inst); DualityBio (Inst); EMD Serono (Inst); EpicentRx (Inst); Exact Sciences (Inst); F Hoffmann-LaRoche Ltd. (Inst); Five Prime Therapeutics (Inst); G1 Therapeutics (Inst); GBG Forschungs (Inst); Genentech (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gynecologic Oncology Group (Inst); Halozyme (Inst); Immunicum (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); InhibRx (Inst); Janssen (Inst); Jiangsu Hengrui Medicine (Inst); Johnson & Johnson (Inst); Lantern Pharma (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Moffitt (Inst); National Surgical Adjuvant Breast and Bowel Project (Inst); Nektar (Inst); NiKang Therapeutics (Inst); Novartis (Inst); OncoC4 (Inst); OncoMed (Inst); Pfizer (Inst); PharmaMar (Inst); Plexxikon (Inst); Pronova (Inst); Regeneron (Inst); Regeneron (Inst); Roche (Inst); Sarah Cannon Research Institute (Inst); Seagen (Inst); Spectrum Pharmaceuticals (Inst); SWOG (Inst); Systimmune (Inst); Zymeworks (Inst)
 
Matthew Katz
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Alcresta Therapeutics; Nestle health science; Taiho Oncology
Travel, Accommodations, Expenses - Intuitive Surgical
 
Anthony Yang
Research Funding - Boston Scientific (Inst)
 
Ronald Weigel
No Relationships to Disclose
 
David Odell
No Relationships to Disclose